To learn more about Transplant Center Specific Analysis (TCSA), see the topics listed below:
Last modified:
Nov 28, 2023
- Welcome
- Public Health Authority and Protected Health Information
- Protocols and Consents
- Fee Schedule
- Access to CIBMTR Systems
- Center Participation
- Continuous Process Improvement Program (CPI)
- Center Compliance
- Regulatory Documentation Standards
- Form Completion Standards
- CPI Resources
- Consecutive Transplant Audit (CTA)
- Step 1: Report Infusions in FormsNet3
- Step 2: US Centers – Submit CTA List to CIBMTR
- Step 2: International Centers – Submit CTA List to CIBMTR
- Step 3: CTA Discrepancy Process
- Downloading CTA Files
- Center Volume Data Reports (CVDR)
- Transplant Center Specific Analysis (TCSA)
- FormsNet3 Process and Tool Instructions
- Data Collection and Quality
- FormsNet3
- AGNIS
- How Forms Come Due
- Cellular Therapy
- Correcting Historical Data
- Primary Disease and Disease Forms Due
- Acute Myelogenous Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Acute Leukemias of Mixed or Ambiguous Lineage
- Chronic Myelogenous Leukemia (CML)
- Myelodysplastic (MDS)
- Myeloproliferative Neoplasms (MPN)
- Other Leukemia
- Hodgkin and Non-Hodgkin Lymphoma
- NHL-Waldenstrom
- Multiple Myeloma/Plasma Cell Disorder (PCD)
- Solid Tumors
- Aplastic Anemia
- Inherited Bone Marrow Failure Syndromes
- Hemoglobinopathies
- Disorders of the Immune System
- Inherited Abnormalities of Platelets
- Inherited Disorders of Metabolism
- Histiocytic Disorders
- Autoimmune Diseases
- Quarterly Form Revision Schedule
- Monthly Maintenance Items for FormsNet3
- NMDP Forms
- Corporate Studies and Registries
- Acronyms
- Quick Links
- Contact Us